Yi Y Zuo Selected Research

Pulmonary Surfactants (Pulmonary Surfactant)

12/2017	Mesoporous carbon nanomaterials induced pulmonary surfactant inhibition, cytotoxicity, inflammation and lung fibrosis.
9/2017	Impact of ventilation-induced lung injury on the structure and function of lamellar bodies.
9/2016	The effect of diet-induced serum hypercholesterolemia on the surfactant system and the development of lung injury.
6/2016	The effect of matrix metalloproteinase-3 deficiency on pulmonary surfactant in a mouse model of acute lung injury.
4/2014	Long-chain acyl-CoA dehydrogenase deficiency as a cause of pulmonary surfactant dysfunction.
1/2012	Biophysical interaction between corticosteroids and natural surfactant preparation: implications for pulmonary drug delivery using surfactant a a carrier.
7/2011	Comparative study of clinical pulmonary surfactants using atomic force microscopy.
9/2008	Atomic force microscopy studies of functional and dysfunctional pulmonary surfactant films, II: albumin-inhibited pulmonary surfactant films and the effect of SP-A.
3/2005	Poly(ethylene glycol) (PEG) enhances dynamic surface activity of a bovine lipid extract surfactant (BLES).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yi Y Zuo Research Topics

Disease

6	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 09/2016 - 03/2005
3	Lung Diseases (Lung Disease) 01/2019 - 01/2012
3	Lung Injury 09/2017 - 09/2015
2	COVID-19 01/2021 - 12/2020
2	Pneumonia (Pneumonitis) 10/2020 - 01/2016
2	Embolism (Embolus) 01/2020 - 01/2017
2	Inflammation (Inflammations) 12/2017 - 06/2016
2	Infections 01/2016 - 09/2015
2	Bacterial Infections (Bacterial Infection) 01/2016 - 01/2015
1	Neoplasms (Cancer) 04/2022
1	Newborn Respiratory Distress Syndrome 01/2021
1	Sepsis (Septicemia) 10/2020
1	Genetic Predisposition to Disease (Genetic Predisposition) 10/2020
1	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2018
1	Fibrosis (Cirrhosis) 12/2017
1	Hypercholesterolemia 09/2016
1	Hypoxia (Hypoxemia) 06/2016
1	Acute Lung Injury 06/2016
1	Human Influenza (Influenza) 09/2015
1	Muscle Cramp (Cramp) 01/2015
1	Bacterial Pneumonia 01/2015
1	Long-chain acyl-CoA dehydrogenase deficiency 04/2014
1	Infant Death 04/2014
1	Asthma (Bronchial Asthma) 01/2012
1	Respiratory Tract Diseases (Respiratory Tract Disease) 07/2011

Drug/Important Bio-Agent (IBA)

9	Surface-Active Agents (Surfactants)IBA 01/2021 - 09/2008
9	Pulmonary Surfactants (Pulmonary Surfactant)IBA 12/2017 - 03/2005
2	IgA receptor (protein B)IBA 10/2020 - 01/2016
2	LipidsIBA 01/2020 - 01/2015
2	Pharmaceutical PreparationsIBA 01/2019 - 01/2015
2	Fatty Acids (Saturated Fatty Acids)IBA 09/2015 - 04/2014
1	matrigelIBA 04/2022
1	AerosolsIBA 12/2020
1	Virus ReceptorsIBA 12/2020
1	Proteins (Proteins, Gene)FDA Link 03/2018
1	Amyloid (Amyloid Fibrils)IBA 03/2018
1	CarbonIBA 12/2017
1	CholesterolIBA 09/2016
1	AcidsIBA 09/2016
1	SolutionsIBA 01/2016
1	Carnitine (L-Carnitine)FDA LinkGeneric 09/2015
1	acylcarnitineIBA 09/2015
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2015
1	Adenosine Monophosphate (AMP)IBA 01/2015
1	Antimicrobial PeptidesIBA 01/2015
1	AntigensIBA 04/2014
1	SteroidsIBA 01/2012
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2012
1	AlbuminsIBA 09/2008
1	Blood Proteins (Serum Proteins)IBA 09/2008

Therapy/Procedure

3	Therapeutics 01/2021 - 10/2008